Monday, May 22, 2017

Banner Image - Patient Safety, Product Integrity, Fair Pricing

Intravenous Immune Globulin Improves Systemic Sclerosis Symptoms

Elderly women grabbing her wrist in pain

In this Issue


•	IVIG/Albumin Supply Index
•	Open Market Pricing
•	New Products from FFF
•	Current Medicare IVIG / SCIG Rates
•	Resources
•	Subscribe to IG Living and BioSupply Trends Quarterly

Administration of high-dose intravenous immune globulin significantly improved muscle and joint pain, muscle weakness and markers of systemic inflammation, according to a retrospective evaluation of 46 systemic sclerosis patients at 19 French centers. [ read more ]

Study Finds Blood Plasma Can Restore Brain Function

Results from a new study show that brain function can be restored by human blood plasma. And, the younger the source of the blood plasma, the better the results. [ read more ]

New Educational Initiative Introduced to Raise Awareness of Chronic Care Management

Connected Care is a new educational initiative to raise awareness of the benefits of chronic care management (CCM) services for Medicare beneficiaries with multiple chronic conditions and to provide healthcare professionals with support to implement CCM programs. [ read more ]

Industry News

From Shire

Shire, manufacturer of immune globulin for the treatment of primary immunodeficiency (PI), has launched a social campaign, #PIPostsThanks, to spotlight the unsung heroes who make a difference in the lives of people living with PI.
[ read more ]

From Samsung Bioepis

Renflexis (infliximab-abda), the second biosimilar to Remicade (infliximab, Janssen Biotech), has been approved by the U.S. Food and Drug Administration to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis and plaque psoriasis. [ read more ]

From Pfizer

The U.S. Food and Drug Administration has approved BAVENCIO (avelumab) for the treatment of patients with locally advanced or metastatic bladder cancer.
[ read more ]

IVIG & Albumin Supply Index

IVIG and Albumin Supply Index from February 2017 - May 2017

Log in to BioSupply for IVIG and Albumin Product Pricing

What's New at FFF

• HYDROXYPROGESTERONE CAPROATE (Mylan/ANI.)

HYDROXYPROGESTERONE CAPROATE (Makena) is a synthetic progestin indicated for reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth. It is available in an injectable oil solution (250 mg/mL) for intramuscular administration in the upper outer quadrant of the gluteus maximus.

For more information about HYDROXYPROGESTERONE CAPROATE, login to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective April 1, 2017, through June 30, 2017.

Product	J Codes	ASP + 6% (before sequester)	ASP + 4.3%* (after sequester)
IVIG
Carimune NF	J1566	$65.28	$64.23
Flebogamma	J1572	$60.35	$59.38
Gammagard S/D	J1566	$65.28	$64.23
Gammaplex	J1557	$83.23	$81.90
Octagam	J1568	$72.17	$71.02
Privigen	J1459	$77.73	$76.49
SCIG
Hizentra	J1559	$98.26	$96.68
HyQvia	J1575	$129.56	$127.48
IVIG / SCIG
Gammagard Liquid	J1569	$80.86	$79.57
Gammaked	J1561	$67.86	$66.77
Gamunex-C	J1561	$67.86	$66.77

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.
** Cuvitru does not yet have Medicare rates.

Log in to BioSupply for Immune Globulin Products

Resources

FFF customers may order the following complementary resources to help you with your practice:


•	IG Immune Globulin (Human)
•	Hyperimmune Globulins
•	Anti-Inhibitor, Factor VIIa & IX
•	Factor VIII & von Willebrand Factor
•	Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

This email was sent by: %%Member_Busname%%, %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
Manage preferences: Privacy Policy, Update Profile, Unsubscribe.